8 years ago

Small Pharma Secures £970k to Develop Rapid-Acting Antidepressant

  • Small Pharma, a UK-based pharmaceutical startup, has raised £970k in funding

  • The funding includes £830k from a round led by Chris Torrance, co-founder of Horizon Discovery and PhoreMost, along with participation from the Angel CoFund, pharma sector experts, and investors, and £140k from Innovate UK

  • This investment will be used to develop a rapid-acting drug for severe depression patients and prepare for clinical trials

  • Small Pharma focuses on low-cost pharmaceutical product development and has a unique IP strategy.

      • ProblemHealthcare

      "Millions of people worldwide suffer from severe depression and existing treatments are often slow acting and ineffective."

      Solution

      "Small Pharma is developing a rapid-acting drug for severe depression based on a derivative of ketamine, a drug that has shown promise in clinical trials for treating depression."

      Covered on